{"id":875,"date":"2026-09-02T06:35:32","date_gmt":"2026-09-02T06:35:32","guid":{"rendered":"https:\/\/nhdbio.com\/status\/retatrutide\/"},"modified":"2026-09-04T06:56:43","modified_gmt":"2026-09-04T06:56:43","slug":"retatrutide","status":"publish","type":"page","link":"https:\/\/nhdbio.com\/fr\/status\/retatrutide\/","title":{"rendered":"Statut de d\u00e9veloppement et d'approbation de Retatrutide"},"content":{"rendered":"

Ce statut d\u00e9crit le programme de m\u00e9decine exp\u00e9rimentale et de d\u00e9veloppement public de Lilly. Il n'\u00e9tablit pas l'identit\u00e9, la formulation, la s\u00e9curit\u00e9, l'efficacit\u00e9 ou le statut juridique d'un mat\u00e9riel de recherche de catalogue utilisant le m\u00eame nom.<\/p>","protected":false},"excerpt":{"rendered":"

Lilly identifie le retatrutide comme un triple agoniste exp\u00e9rimental et d\u00e9clare qu'il n'est pas actuellement approuv\u00e9 par FDA. Les annonces principales de la phase 3 ne constituent pas une approbation de commercialisation ou un ensemble complet de preuves \u00e9valu\u00e9es par des pairs.<\/p>","protected":false},"author":0,"featured_media":0,"parent":20,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-875","page","type-page","status-publish","hentry"],"yoast_head":"\nRetatrutide Development and Approval Status | Research Knowledge Center<\/title>\n<meta name=\"description\" content=\"Lilly identifies retatrutide as an investigational triple agonist and states that it is not currently approved by FDA. Phase 3 topline announcements do not constitute marketing approval or a complete peer-reviewed evidence package.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/status\/retatrutide\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Development and Approval Status\" \/>\n<meta property=\"og:description\" content=\"Lilly identifies retatrutide as an investigational triple agonist and states that it is not currently approved by FDA. Phase 3 topline announcements do not constitute marketing approval or a complete peer-reviewed evidence package.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/status\/retatrutide\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T06:56:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/status\\\/retatrutide\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/status\\\/retatrutide\\\/\",\"name\":\"Retatrutide Development and Approval Status | Research Knowledge Center\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"datePublished\":\"2026-09-02T06:35:32+00:00\",\"dateModified\":\"2026-09-04T06:56:43+00:00\",\"description\":\"Lilly identifies retatrutide as an investigational triple agonist and states that it is not currently approved by FDA. Phase 3 topline announcements do not constitute marketing approval or a complete peer-reviewed evidence package.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/status\\\/retatrutide\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/status\\\/retatrutide\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/status\\\/retatrutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Status Tracker\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/status\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide Development and Approval Status\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Statut de d\u00e9veloppement et d'approbation de Retatrutide | Centre de connaissances de recherche","description":"Lilly identifie le retatrutide comme un triple agoniste exp\u00e9rimental et d\u00e9clare qu'il n'est pas actuellement approuv\u00e9 par FDA. Les annonces principales de la phase 3 ne constituent pas une approbation de commercialisation ou un ensemble complet de preuves \u00e9valu\u00e9es par des pairs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/status\/retatrutide\/","og_locale":"fr_FR","og_type":"article","og_title":"Retatrutide Development and Approval Status","og_description":"Lilly identifies retatrutide as an investigational triple agonist and states that it is not currently approved by FDA. Phase 3 topline announcements do not constitute marketing approval or a complete peer-reviewed evidence package.","og_url":"https:\/\/nhdbio.com\/fr\/status\/retatrutide\/","og_site_name":"NHD","article_modified_time":"2026-09-04T06:56:43+00:00","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/status\/retatrutide\/","url":"https:\/\/nhdbio.com\/status\/retatrutide\/","name":"Statut de d\u00e9veloppement et d'approbation de Retatrutide | Centre de connaissances de recherche","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"datePublished":"2026-09-02T06:35:32+00:00","dateModified":"2026-09-04T06:56:43+00:00","description":"Lilly identifie le retatrutide comme un triple agoniste exp\u00e9rimental et d\u00e9clare qu'il n'est pas actuellement approuv\u00e9 par FDA. Les annonces principales de la phase 3 ne constituent pas une approbation de commercialisation ou un ensemble complet de preuves \u00e9valu\u00e9es par des pairs.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/status\/retatrutide\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/status\/retatrutide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/status\/retatrutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Product Status Tracker","item":"https:\/\/nhdbio.com\/status\/"},{"@type":"ListItem","position":3,"name":"Retatrutide Development and Approval Status"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/pages\/875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=875"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/pages\/875\/revisions"}],"predecessor-version":[{"id":1135,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/pages\/875\/revisions\/1135"}],"up":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/pages\/20"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}